TEVA · Insider Trading
Teva Pharmaceutical Industries Limited
Every open-market purchase and sale reported by TEVA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-22 | Roberto Mignone | Director | Sell | −367,600 | −$14.36M |
| 2026-09-22 | Brian Savage | Interim Chief Legal Officer | MIXED | −2,839 | −$128.96K |
| 2026-08-25 | Ronit Satchi-Fainaro | Director | Sell | −415 | −$15.46K |
| 2026-08-25 | Amir Weiss | Chief Accounting Officer | MIXED | −6,945 | −$306.28K |
| 2026-08-19 | Evan Lippman | EVP, Business Development | Sell | −18,600 | −$680.29K |
| 2026-08-10 | Tal Zvi Zaks | Director | Sell | −17 | −$593 |
| 2026-08-05 | Eric A Hughes | See "Remarks" | MIXED | +27,166 | −$892.05K |
| 2026-08-05 | Placid Jover | See "Remarks" | MIXED | — | −$447.35K |
| 2026-06-22 | Matthew Shields | EVP, Global Operations | Sell | −9,989 | −$321.55K |
| 2026-06-16 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Sell | −106,563 | −$3.63M |
| 2026-06-08 | Ronit Satchi-Fainaro | Director | M | +14,492 | — |
| 2026-06-08 | Amir Elstein | Director | M | +14,492 | — |
| 2026-06-08 | Tal Zvi Zaks | Director | M | +14,492 | — |
| 2026-06-08 | Gerald M Lieberman | Director | M | +14,492 | — |
| 2026-06-08 | Perry Nisen | Director | M | +14,492 | — |
| 2026-06-08 | Rosemary A Crane | Director | M | +14,492 | — |
| 2026-06-08 | Chen Lichtenstein | Director | M | +14,492 | — |
| 2026-06-08 | Sol J Barer | Director | M | +21,739 | — |
| 2026-06-08 | Richard D Francis | President and CEO | MIXED | +6,890 | −$211.36K |
| 2026-06-08 | Roberto Mignone | Director | M | +14,492 | — |
| 2026-06-04 | Matthew Shields | EVP, Global Operations | MIXED | — | −$532.33K |
| 2026-06-01 | Sol J Barer | Director | A | +10,863 deriv. | — |
| 2026-06-01 | Amir Elstein | Director | A | +7,242 deriv. | — |
| 2026-06-01 | Ronit Satchi-Fainaro | Director | A | +7,242 deriv. | — |
| 2026-06-01 | Perry Nisen | Director | A | +7,242 deriv. | — |
| 2026-06-01 | Tal Zvi Zaks | Director | A | +7,242 deriv. | — |
| 2026-06-01 | Chen Lichtenstein | Director | A | +7,242 deriv. | — |
| 2026-06-01 | Gerald M Lieberman | Director | A | +7,242 deriv. | — |
| 2026-06-01 | Roberto Mignone | Director | A | +7,242 deriv. | — |
| 2026-06-01 | Rosemary A Crane | Director | A | +7,242 deriv. | — |
| 2026-05-18 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Sell | −153,251 | −$5.46M |
| 2026-05-18 | Evan Lippman | EVP, Business Development | MIXED | +44,191 | −$1.48M |
| 2026-05-07 | Richard Daniell | EVP, Europe Commercial | Sell | −30,000 | −$1.06M |
| 2026-05-07 | Amir Weiss | Chief Accounting Officer | Sell | −10,679 | −$384.44K |
| 2026-05-04 | Christine Fox | EVP, U.S. Commercial | Sell | −21,258 | −$750.62K |
| 2026-05-04 | Mark Sabag | See "Remarks" | Sell | −144,180 | −$5.05M |
| 2026-03-19 | Mark Sabag | See "Remarks" | Sell | −62,102 | −$1.87M |
| 2026-03-09 | Placid Jover | See "Remarks" | MIXED | — | −$448.11K |
| 2026-03-09 | Matthew Shields | EVP, Global Operations | MIXED | — | −$547.70K |
| 2026-03-09 | Christine Fox | EVP, U.S. Commercial | MIXED | +9,895 | −$250.94K |
| 2026-03-09 | Eric A Hughes | See "Remarks" | MIXED | +10,121 | −$301.89K |
| 2026-03-09 | Mark Sabag | See "Remarks" | M | +15,723 | — |
| 2026-03-09 | Brian Savage | Interim Chief Legal Officer | MIXED | +2,453 | −$35.69K |
| 2026-03-09 | Amir Weiss | Chief Accounting Officer | M | +3,537 | — |
| 2026-03-09 | Richard Daniell | EVP, Europe Commercial | MIXED | — | −$547.70K |
| 2026-03-09 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | M | +19,916 | — |
| 2026-03-09 | Richard D Francis | President and CEO | MIXED | +22,427 | −$634.16K |
| 2026-03-06 | Matthew Shields | EVP, Global Operations | A | +33,424 deriv. | — |
| 2026-03-06 | Evan Lippman | EVP, Business Development | A | +27,347 deriv. | — |
| 2026-03-06 | Eric A Hughes | See "Remarks" | MIXED | +11,974 | −$366.10K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Amir Elstein | Director | 2,118,455 | $85.56M |
| Richard D Francis | President and CEO | 1,177,529 | $47.56M |
| Sol J Barer | Director | 448,011 | $18.10M |
| Eric A Hughes | See "Remarks" | 134,877 | $5.45M |
| Gerald M Lieberman | Director | 130,149 | $5.26M |
| Rosemary A Crane | Director | 127,739 | $5.16M |
| Roberto Mignone | Director | 119,807 | $4.84M |
| Perry Nisen | Director | 119,807 | $4.84M |
| Ronit Satchi-Fainaro | Director | 111,986 | $4.52M |
| Mark Sabag | See "Remarks" | 80,760 | $3.26M |
| Janet S. Vergis | Director | 73,697 | $2.98M |
| Tal Zvi Zaks | Director | 73,247 | $2.96M |
| Eliyahu Sharon Kalif | EVP, Chief Financial Officer | 65,621 | $2.65M |
| Christine Fox | EVP, U.S. Commercial | 63,647 | $2.57M |
| Richard Daniell | EVP, Europe Commercial | 55,755 | $2.25M |
| Evan Lippman | EVP, Business Development | 25,591 | $1.03M |
| Varda Shalev | Director | 22,504 | $908.94K |
| Chen Lichtenstein | Director | 19,296 | $779.37K |
| Brian Savage | Interim Chief Legal Officer | 15,842 | $639.86K |
| Amir Weiss | Chief Accounting Officer | 13,071 | $527.94K |
| David R. McAvoy | EVP, Chief Legal Officer | 13,027 | $526.16K |
| Placid Jover | See "Remarks" | 6,774 | $273.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TEVA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.